Leflunomide Tablet, Film Coated
Product Images NDC 68071-3764

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 68071-3764). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3764 9)

Packaging label for Leflunomide 20 mg film-coated tablets by NuCare Pharmaceuticals, Inc. The label indicates a quantity of 90 tablets. Each triangular tablet is white to off-white, debossed with "58" on one side and "11" on the other. The label includes storage instructions, manufacturer details, and FDA warning to keep out of reach of children.*

FDA Label Image

Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 01)

Chemical structure of leflunomide showing its molecular components, including a trifluoromethyl-substituted phenyl ring connected to an isoxazole ring with associated functional groups.*

FDA Label Image

Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 02)

Chemical structure of teriflunomide, the active metabolite of leflunomide, depicted with molecular bonds and functional groups including a trifluoromethyl-substituted phenyl ring, amide, and nitrile groups.*

FDA Label Image

Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 03)

A bar chart titled '% ACR 20 Responder at Endpoint' comparing response rates at different trial endpoints for drugs leflunomide (L), methotrexate (M), placebo (P), and sulfasalazine (S). The chart shows percentage response rates for three trials, with endpoints at 6 or 12 months. Leflunomide generally shows higher response percentages compared to placebo and similar or slightly lower rates compared to methotrexate.*

FDA Label Image

Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 04)

A line graph titled 'Trial 1 ACR Responders Over Time' showing the percentage of responders over a 12-month period for three groups: PL, MTX, and LEF. The x-axis represents time in months (0 to 12) and the y-axis represents the percentage of responders (from -10% to 70%). The graph includes a legend identifying each group by different markers and line styles. A note indicates 'Last Observation Carried Forward.'*

FDA Label Image

Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 05)

A bar graph titled 'Change in Sharp Score' depicting the progression of disease across three clinical trials with different timeframes. The x-axis groups data by treatment: Leflunomide (L), Methotrexate (M), Sulfasalazine (S), and Placebo (P). The y-axis measures progression in Sharp Score, with values shown for each treatment group in all three trials.*

FDA Label Image

Image (B9ae0559 441f 4be3 88e5 336b2bbfa2b2 06)

A bar chart titled 'Change in Functional Ability Measure' showing improvement values measured by the HAQ Disability Index across three trials (Trial 1: 12 months, Trial 2: 6 months, Trial 3: 12 months). The chart compares treatment groups labeled L (Leflunomide), M (Methotrexate), P (Placebo), and S (Sulfasalazine) with bars indicating different degrees of functional ability improvement or decline.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.